drugset
drugset / Trial / NCT03277274

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

NCT03277274 ↗

Phase 1 Completed 25 enrolled Takeda
Non-randomizedSequentialOpen-labelOther

Summary

The purpose of this study is to evaluate the effect of varying degrees of hepatic function on the single dose PK of IV TAK-954.

Timeline

Start
2017-11-09
Primary completion
2018-09-01
Completion
2018-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject felcisetrag Small molecule 0.2 mg Intravenous

Indications

No indication recorded.